News
AXGN
42.06
-3.11%
-1.35
AxoGen Insiders Quietly Unload a Wave of Shares in Major Cash-Out Spree
TipRanks · 1d ago
Axogen director John Johnson disposes of 11,050 shares worth $478,966.75
PUBT · 1d ago
Axogen director Kathy Johnson Weiler disposes 16,344 shares for $720,448.7
PUBT · 1d ago
Axogen CMO Jens Kemp disposes 4,000 shares worth $173,761.20
PUBT · 1d ago
Axogen CFO Lindsey Hartley disposes 1,051 shares worth $45,882.17
PUBT · 1d ago
Axogen Sales VP Doris Quackenbush sells 3,878 shares worth $168,718.15
PUBT · 1d ago
Axogen files Form 3 showing Sales VP Doris Quackenbush beneficial ownership
PUBT · 1d ago
Canaccord Genuity Sticks to Its Buy Rating for AxoGen (AXGN)
TipRanks · 5d ago
Weekly Report: what happened at AXGN last week (0427-0501)?
Weekly Report · 5d ago
TELA BIO INC - CHAIRMAN DOUG EVANS, KURT AZARBARZIN, VINCE BURGESS, FEDERICA O’BRIEN TO DEPART BOARD
Reuters · 04/30 20:43
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (NAGE)
TipRanks · 04/30 12:21
Axogen to present at Bank of America Global Healthcare Conference
PUBT · 04/30 11:00
Axogen Price Target Raised to $50.00/Share From $45.00 by Canaccord Genuity
Dow Jones · 04/29 19:43
Axogen Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/29 19:43
AxoGen price target raised to $48 from $41 at Raymond James
TipRanks · 04/29 16:57
Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), AxoGen (AXGN)
TipRanks · 04/29 16:51
Axogen Is Maintained at Market Outperform by Citizens
Dow Jones · 04/29 15:22
Citizens Maintains Market Outperform on Axogen, Raises Price Target to $50
Benzinga · 04/29 15:12
Axogen Is Maintained at Overweight by Wells Fargo
Dow Jones · 04/29 15:10
Axogen Price Target Raised to $48.00/Share From $40.00 by Wells Fargo
Dow Jones · 04/29 15:10
More
Webull provides a variety of real-time AXGN stock news. You can receive the latest news about Axogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.